All peptides

Semax

An ACTH(4-10) analog used in Russia for stroke recovery and cognitive disorders, notable for BDNF upregulation.

Regulatory status
Approved in Russia; not FDA approved
Half-life
Minutes (effects persist hours)
Route
Intranasal or subcutaneous
Evidence
Limited human trials or approved outside the US

Mechanism of action

Increases BDNF and NGF expression and modulates dopaminergic/serotonergic tone.

Studied and reported uses

  • Cognitive performance
  • Stroke rehabilitation
  • Attention support

Dosing information

Reported range200–600 mcg daily intranasally

Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.

Side effects

  • Nasal irritation
  • Overstimulation
  • Irritability

Research evidence

Stroke trials

Improved neurological recovery scores (Russia).